frederik_wilkinson

Impax Laboratories parts with CEO

pharmafile | December 22, 2016 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Impax Laboratories 

Impax Laboratories announced on 20 December that CEO Frederik Wilkinson has left his position of president and CEO, as well as his position on the board of directors, effective immediately. Wilkinson has been with the company for two years, after steering its Parkinson’s drug, Rytary, through the FDA approval process due to issues with the manufacturing facility.

“Fred has been instrumental in Impax’s ability to remove the warning letter regarding the Company’s Hayward facility, which has allowed us to regain generic approvals from that facility,” said Robert L. Burr, chairman of the board of directors at Impax Laboratories.

“I am extremely proud of the many accomplishments Impax has realized over the past several years,” said Mr. Wilkinson. “I am truly grateful for the support I’ve received from the Board of Directors, the executive management team and most importantly, our highly dedicated employees. I am confident that Impax is well positioned for great success in the future.”

Impax has drafted in Kevin Buchi as interim president and CEO of the company until a long-term replacement has been found. Buchi will be retiring from his current position of president and CEO of TetraLogic Pharmaceuticals and therefore will be free to take temporary charge of Impax.

Related Content

turing_pharma

Turing will drop price of Daraprim following outrage

Martin Shkreli, whose company Turing Pharmaceuticals increased the price of Daraprim more than fifty-fold overnight, …

Latest content